Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Effects of dexmedetomidine on delirium duration of non-intubated ICU patients (4D trial): study protocol for a randomized trial

Abstract : Delirium during intensive care unit (ICU) stay is frequent and associated with significant morbidity, mortality and healthcare-related costs. International guidelines suggest its prevention. However, curative treatment remains unclearly established. Despite contradictory and ambiguous academic literature, international guidelines suggest the use of second-generation (atypical) antipsychotics over haloperidol. However, haloperidol remains the most widely used neuroleptic worldwide as a first-line treatment of agitation and/or delirium. Dexmedetomidine, an alpha2-adrenergic receptors agonist, has shown its efficiency in the treatment of delirium in intubated patients but also in its prevention. Dexmedetomidine represents a widely used alternative to haloperidol. Only few studies have compared the efficacy of dexmedetomidine in non-intubated ICU patients as a first-line curative treatment of delirium. The main objective of the 4D trial is to demonstrate that dexmedetomidine decreases delirium duration compared to placebo.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-01815585
Contributeur : Dominique Mornet <>
Soumis le : lundi 4 mai 2020 - 09:47:24
Dernière modification le : vendredi 15 mai 2020 - 14:05:29

Fichier

2018 Louis et al., Effects of ...
Fichiers produits par l'(les) auteur(s)

Identifiants

Citation

Clémence Louis, Thomas Godet, Gerald Chanques, Nathalie Bourguignon, Dominique Morand, et al.. Effects of dexmedetomidine on delirium duration of non-intubated ICU patients (4D trial): study protocol for a randomized trial. Trials, BioMed Central, 2018, 19 (1), pp.307. ⟨10.1186/s13063-018-2656-x⟩. ⟨hal-01815585⟩

Partager

Métriques

Consultations de la notice

343

Téléchargements de fichiers

31